Miscellaneous
Comparison of Aspirin Resistance in Type 1 Versus Type 2 Diabetes Mellitus

https://doi.org/10.1016/j.amjcard.2005.09.093Get rights and content

This study sought to determine the frequency of aspirin resistance in an ambulatory population of patients with type 1 diabetes mellitus (T1D) or type 2 diabetes mellitus (T2D). Platelet aggregation was assessed during the routine clinical evaluation of 203 ambulatory patients with diabetes (T1D, n = 92; T2D, n = 111) who were recommended aspirin for primary or secondary cardiovascular protection. Consecutively received laboratory samples were evaluated using the Ultegra Rapid Platelet Function Assay-ASA. Resistance to aspirin was detected in 18.7% of diabetic aspirin users, with similar rates in T1D (21.7%, p = 0.5) and T2D (16.2%, p = 0.6). Aspirin resistance was not related to age, glycohemoglobin, total cholesterol, or a history of cardiovascular disease. Female gender was a strong independent predictor of aspirin resistance in patients with T1D (p = 0.001). Platelet aggregation was correlated with high-density lipoprotein (HDL) cholesterol in the entire cohort (r = 0.21, p = 0.005) and in patients with T1D (r = 0.32, p = 0.04) or T2D (r = 0.21, p = 0.04), such that patients with low HDL cholesterol levels were more likely to be aspirin sensitive. The results suggest that aspirin can inhibit platelet aggregation in most patients with diabetes and is a reasonable first-line antiplatelet agent in patients with diabetes.

References (20)

There are more references available in the full text version of this article.

Cited by (56)

  • Interventions for coronary artery disease (Surgery vs Angioplasty) in diabetic patients

    2014, Endocrinology and Metabolism Clinics of North America
    Citation Excerpt :

    The issue of acetylsalicylic acid (ASA) resistance is significant in revascularized patients with DM.80 More than 20% of patients with DM seem to be ASA resistant.81 Colchicine may reduce ISR and TVR in BMS used for patient with DM who have contraindications to dual antiplatelet therapy.82

  • Use of antiaggregants in diabetes

    2010, Avances en Diabetologia
View all citing articles on Scopus

Dr. Goldfine was supported by Grant NIH K23-DK02795 from the National Institutes of Health, Bethesda, Maryland. Dr. Silver was supported by the William Randolph Hearst Foundation, New York, New York.

View full text